Share Name Share Symbol Market Type Share ISIN Share Description
Sensyne Health Plc LSE:SENS London Ordinary Share GB00BYV3J755 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 152.50 21,763 08:00:18
Bid Price Offer Price High Price Low Price Open Price
150.00 155.00 155.75 152.50 152.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.14 -18.99 -19.00 251
Last Trade Time Trade Type Trade Size Trade Price Currency
16:15:32 O 104 150.55 GBX

Sensyne Health (SENS) Latest News

More Sensyne Health News
Sensyne Health Investors    Sensyne Health Takeover Rumours

Sensyne Health (SENS) Discussions and Chat

Sensyne Health Forums and Chat

Date Time Title Posts
02/8/202122:01Sensyne Health - Clinical AI546
27/11/201912:04Sensyne Health PLC83

Add a New Thread

Sensyne Health (SENS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-08-04 15:15:34150.55104156.57O
2021-08-04 14:43:39151.00531801.81O
2021-08-04 14:35:18152.002,3803,617.60O
2021-08-04 14:10:48153.00152232.56O
2021-08-04 13:34:04152.007161,088.32O
View all Sensyne Health trades in real-time

Sensyne Health (SENS) Top Chat Posts

Sensyne Health Daily Update: Sensyne Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SENS. The last closing price for Sensyne Health was 152.50p.
Sensyne Health Plc has a 4 week average price of 140p and a 12 week average price of 137.50p.
The 1 year high share price is 191p while the 1 year low share price is currently 31p.
There are currently 164,799,139 shares in issue and the average daily traded volume is 140,658 shares. The market capitalisation of Sensyne Health Plc is £251,318,686.98.
rambutan2: Noted: Oxford, U.K. 02 August 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical Clinical AI company, today announces that it has reached a milestone of access to a combined clinical research, clinical trial and real world de-identified and anonymised dataset of over 60 million patients. This enlarged dataset results from both Sensyne's investment in virtual clinical development company, Phesi Inc. in January 2021, and the progress made by Sensyne and Phesi in building their respective data platforms. https://uk.advfn.com/stock-market/london/sensyne-health-SENS/share-news/Sensyne-Health-PLC-Sensyne-dataset-reaches-60m-pat/85721663
billy3: Small recent rise partly helped by tip in the Telegraph. https://www.telegraph.co.uk/investing/shares/four-fastest-growing-stocks-investors-should-buy/ Four of the fastest-growing stocks investors should buyExperts predict these companies will offer big rewards to adventurous investorsTrying to find the fastest-growing stocks in the hope they will become world-leading companies is not the right strategy for every investor. But for those investing for the long term, who can stomach violent share price swings, the rewards can be immense.Buying the right companies is no easy task, however. “Growth” investors search for companies that are growing their sales substantially every year. While they may not always be profitable, investors in these companies are betting that by getting in early, they will reap big rewards when their strong growth leads to profits.It can be a risky strategy, but fund managers believe the following stocks boast both the strong sales growth and resilient business models needed to make them compelling investments.Sensyne HealthBritish healthcare technology firm Sensyne Health uses anonymous patient data to accelerate the development of new medicines.Neil Goddin, manager of the Artemis Positive Future fund, said Sensyne was changing how drugs were developed and the treatment given to sick patients. "It has over 10 apps being used today, ranging from self-monitoring of blood glucose levels and coronavirus monitoring, right through to monitoring of heart failure. Now revenues are really taking off,” he said.The first year of sales – 2018 – generated £81,000 in revenue. In 2019 this grew by 68pc, before explosive growth last year, when revenue surged 1,500pc to more than £2m. By the end of 2024 sales are expected to have risen to £80m, according to Mr Goddin.Sensyne's share price performance offers a glimpse of how volatile growth stocks can be, however. After floating in 2018 at 175p per share, they tumbled to a low of just over 31p, before rising nearly five-fold to today's 150p price.
billy3: WoooooooooHoooooo :-) ‘Significant commercial’ and ‘national̵7; Read back everything said before and this was where it was heading. Adopted by the DHSC and the ONLY product of its type. Sensyne Health PLC MagnifEye Production Contract with UK DHSC 01/06/2021 7:00am UK Regulatory (RNS & others) Sensyne Health (LSE:SENS) Intraday Stock Chart Tuesday 1 June 2021 Click Here for more Sensyne Health Charts. TIDMSENS RNS Number : 3067A Sensyne Health PLC 01 June 2021 MagnifEye Production Contract with the UK's Department of Health & Social Care Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI technology company, today announces it has signed a production contract with the UK's Department of Health & Social Care (DHSC) to use Sensyne's MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government's asymptomatic testing programme. The scope of this contract with DHSC is for a phased national roll-out over a three-month period in care homes, GP practices and selected private sector organisations with large workforces. Revenues will be shared with Excalibur Health Systems under the terms of the exclusive agreement between the two companies. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "This is a significant commercial milestone in Sensyne's development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Department of Health & Social Care to support the UK's national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic."
rambutan2: Courtesy of c itywire today: Sensyne Health (SENS), which develops medical artificial intelligence products, is on track for a ‘major inflection’ in 2022, says Liberum. Analyst Graham Doyle reiterated his ‘buy’ recommendation and target price of 310p on the stock, which closed up 1%, or 1.5p, at 156p on Thursday after releasing a trading update. Revenues of £9m plus were better than Liberum’s forecast. ‘Importantly, on the back of a good start to the year with pharma contract momentum, management provided a positive outlook confirming its confidence in hitting consensus expectations which implies a trebling of revenues to £28m,’ he said. ‘Lastly, after doubling its patient dataset over the past week to 18m, management is now ambitiously targeting 100m patients by the end of 2024.’ Doyle said Sensyne had moved from ‘concept to reality’ and was now ‘beginning to generate material revenues with profitability expected in 2023’, meaning there is ‘a lot more to go for’ in the share price.
billy3: Great update. Plenty of progress and revenue at last. Let’s see where the share price goes and hopefully some good press coverage. ................................................................... Sensyne Health PLC Trading Update 27/05/2021 7:00am UK Regulatory (RNS & others) Sensyne Health (LSE:SENS) Intraday Stock Chart Thursday 27 May 2021 Click Here for more Sensyne Health Charts. TIDMSENS RNS Number : 0094A Sensyne Health PLC 27 May 2021 Sensyne Health Trading Update FY2021 trading performance ahead of market expectations Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ("FY 2021"), and an outlook statement. UPDATE ON TRADING -- Robust financial performance: FY 2021 unaudited revenues of at least GBP9.0 million (FY 2020: GBP2.1 million audited). -- Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the GBP4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ("Excalibur"). -- Cash and cash equivalents were GBP23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: GBP31.7 million audited). -- Fast growth of real world patient database: Acceleration in the growth of Sensyne's de-identified and anonymised real world patient database with access to total of 18.2 million unique records from the UK and the US. -- Access to c.8.5 million patient records in the UK, a three-fold increase during the financial year, following the signing of six new strategic research agreements ("SRAs") with NHS Trusts; provides coverage of c.13% of the UK population and a significant step towards the target of c.20%. -- In May 2021, the Company signed its first two US SRAs with leading healthcare providers St Luke's University Health Network, serving Pennsylvania and New Jersey, and Colorado Center for Personalised Medicine, providing access to 9.8 million patient records in the US. -- Sensyne now has one of the world's fastest growing longitudinal patient datasets, that includes the detailed phenotypic and genomic data needed for life sciences research. -- Life Science commercial agreements: Momentum continues in discovery sciences with new agreements announced with Alexion and Bristol Myers Squibb, and agreement signed with Excalibur Health for AI based diagnostics. Significant opportunity and good traction seen within business development pipeline including ongoing discussions with existing and new clients across the global pharmaceutical and diagnostic industries. -- Phesi collaboration: First commercial agreement as part of strategic collaboration with Phesi Inc., a clinical data specialist, signed with leading pharmaceutical company in May 2021. Additional commercial agreements for clinical trial optimisation expected during the current financial year. -- SENSIGHT Platform: Development of SENSIGHT platform to support rapid interrogation of the real world patient database and industrialisation of our offering to life science companies is on track for launch by mid-2021. -- Diagnostics: Development and launch of MagnifEye (TM) , an AI diagnostic lateral flow test reader during the year. Exclusive licensing and collaboration agreement for lateral flow testing applications secured with Excalibur generating minimum revenues of GBP4.8 million. Additional commercial opportunities for MagnifEye being pursued in the UK and internationally. -- SENSE Platform: Development of the SENSE healthcare platform building a suite of advanced AI enabled tools for use by healthcare systems and the life science industry. Access to recently expanded real world patient datasets and specialist datasets expected to broaden this portfolio of AI enabled software tools. -- Regulatory milestones: . UK MHRA emergency use derogation for MagnifEye received in May 2021. SYNE-COV clinical algorithm for assessing risk for COVID-19 patients admitted to hospital achieved UKCA status in February 2021 and submission to the US Food and Drug Administration of SYNE-GDm in May 2021. SYNE-GDm was submitted for approval under the Medical Device Regulation in August 2020 and a decision is expected soon. -- GDm-Health solution : Patient remote monitoring software for gestational diabetes now used by 56 NHS Trusts helped care for 28,338 pregnancies since launch in the UK. US launch of GDm in partnership with Cognizant in December 2020; uptake has been slower than expected due to impact of Covid-19 pandemic on US healthcare systems and competitive market environment. Other partnership opportunities being explored to support uptake of this software solution in the US market. Accelerating patient data strategy With the signing of two US SRAs recently building on our rapidly growing UK datasets, Sensyne Health is now accelerating its strategy to be a global leader in clinical AI with one of the largest and fastest-growing sets of ethical, de-identified and anonymised real world patient data. Sensyne now has access to a total of 18.2 million unique records from in UK and the US. Sensyne intends to continue to scale its dataset in a highly strategic manner to enhance its provision of high-quality longitudinal health data within the highest quality ethical framework exclusively focused on delivering improved patient care and accelerating medical research. New health care partners are expected to bring geographically diverse data in key therapeutic areas including cardiovascular, oncology and rare diseases. Different data types, including additional deep phenotypic, imaging and genomic data are expected to further enrich the database. In line with its previously announced strategy, Sensyne's focus will be on adding to its strong relationships in the UK and US, followed by expansion into Europe and Asia Pacific to support demand from existing and potential new life sciences customers. The Company currently has a pipeline of growing SRA opportunities under active discussion with healthcare systems to access a further c.40 million unique patient records in the UK and US alone reinforcing that Sensyne is seen as a partner of choice for healthcare systems. As the recent US agreements show, international SRAs are structured to place a greater emphasis on the future royalty opportunity rather than other economic parameters and allow Sensyne to continue to scale its access to global health data sustainably. Sensyne seeks to become a leader in the field by building an ethically-sourced real world dataset of c.100 million patient records by the end of 2024, representative of the patient populations in the key markets of interest to the life sciences industry. OUTLOOK Sensyne's robust financial performance, continued momentum with life sciences and the scale of the opportunities presented to it provides confidence in the future performance of the Company. Sensyne's rapidly growing patient databases and world-class expertise in clinical AI provide the foundation for substantial revenue growth and the potential to achieve global scale. The Company anticipates this revenue growth to be driven by life sciences in the near term, taking a flexible approach to the overall mix and to perform in line with its expectations for FY2022 total revenue. The Company continues to explore strategic opportunities, including acquisitions, that can leverage this strong organic growth and create additional shareholder value. Lord (Paul) Drayson PhD FREng, Chief Executive Officer of Sensyne Health , commented: "Covid-19 has accelerated the demand for deeply curated real world patient data and AI analytical tools to inform effective decision making in the delivery of patient care and the efficient development of new medicines. Sensyne Health's partnership model for the ethical use of patient data, in partnership with the NHS and US healthcare providers, has enabled it to build a leadership position in clinical AI that is reflected in our robust growth in data and revenues. The Company is now well placed to capitalise on this growth to become the global leader in the ethical application of clinical AI to patient data."
rambutan2: Deserves a full posting imho: Oxford, U.K, and Dover, Delaware, USA 24 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI company, today announces that it has signed its second Strategic Research Agreement ("SRA") in the U.S. with the Colorado Center for Personalized Medicine ("CCPM"), htTps://www.cobiobank.org a partnership between non-profit health system UCHealth htTPs://www.uchealth.org/today/ and the University of Colorado Anschutz Medical Campus hTtps://www.cuanschutz.edu The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate medical research. This is in line with Sensyne's strategy of building a world-leading health data platform with industrial scale and robust patient data protection. The uptake of Sensyne's model in the U.S. demonstrates growing appetite for more advanced ethical data sourcing supported by patient information protection. The CCPM houses one of largest health data warehouses in the United States and has been a pioneer in driving large-scale personalized medicine and return of clinically actionable results through a research biobank, integrating personalized genomic information with clinical data. CCPM's significant advancements in making pharmacogenomics a standard of care are already providing benefits, and with plans to expand the provision of personalized healthcare, patients will soon have access to more clinically-actionable results, including genomic mutations that confer risk to diseases such as cancer and cardiomyopathies. In tandem, through its partnership with UCHealth, CCPM is scaling efforts to include as many as 100,000 additional UCHealth patients per year. The CCPM dataset covers 7.3 million de-identified and anonymised patients, including anonymised patient records from a UCHealth population of approximately 2.4 million active patients and a biobank of >180,000 research participants for which clinical genetic test results are being generated. UCHealth cares for patients through its network of 12 acute-care full-service hospitals and hundreds of clinic locations across Colorado, southern Wyoming and western Nebraska. Consistent with Sensyne's approach with all of its Strategic Research Agreements, research will be undertaken to the highest standards of information governance and data security and in accordance with The Health Insurance Portability and Accountability Act (HIPAA), the U.S. data protection legislation that protects sensitive patient information. All data supplied to Sensyne for research will be de-identified by CCPM beforehand and will remain in the U.S., and the provision of the data will operate under an agreed set of data processing procedures. Under the terms of the agreement, should the medical research undertaken by Sensyne using CCPM's data lead to medical discoveries commercialised by Sensyne, CCPM will share a proportion of Sensyne's revenues generated from that research. The agreement quickly follows Sensyne's first U.S. SRA announced on 21 May 2021 with St. Luke's University Health Network, a leading U.S. health system serving patients in Pennsylvania and New Jersey. These new US partners follow 11 National Health Service ( NHS) Trusts in the U.K., covering more than 13% of the U.K. population, which have partnered with Sensyne sharing anonymised clinical datasets to enable the discovery of new treatments, increase disease understanding, and advance clinical trial design. Kathleen Barnes, PhD, University of Colorado School of Medicine Professor and Director of CCPM , said: "This collaboration will take an already notable program at the CCPM and expand the depth and breadth of its capabilities, allowing us to give more back to patients everywhere through our collaborations. Our partnership with Sensyne Health will lead to an optimization of patient care, using personalized results to better inform research, clinical decision making, and potentially leading to new ways of diagnosing, preventing and treating illnesses." Lord (Paul) Drayson, PhD, CEO of Sensyne Health, said: " This agreement with Colorado Center for Personalized Medicine, covering both genomic and electronic health record data , will enable us to undertake research aimed at a deeper understanding of disease, and to accelerate the development of novel medicines in collaboration with our pharmaceutical partners. I'm delighted to be working with CCPM and excited about the capability that our growing international data collaborative now offers to the global life sciences research community."
billy3: Well it’s gone a little quiet recently but the share price seems steady. Sens seems to release a lot of news on a Friday so we are overdue something. As I’ve mentioned before, the LFT deal with Excalibur could be huge and not priced in. As expected, the government has now confirmed that LFTs are a big part of the way ahead. I was surprised at exactly how big and how many tests will be available. We haven’t seen the results if the pilot yet which includes Sens and they have been paid half a million for. Excalibur can produce 3 million tests per day. If Uk population can be able to test up to twice per week and even get 7 kits at a time at a pharmacist, I see no reason why they can’t shift 3 million a day. So, that’s 21 million tests per week. Even if Sens received 10p per test carried out, that’s a whopping £2.1 million per week !!! I guess we will have to wait for the next report. The positive is that Sens is not a ‘one trick pony’ and this deal is just one element of what they already have and in the pipeline. If Excalibur confirms they will be shipping at Capacity and each kit is linked to the Sens app (which no other her company has where tests can be read and recorded by a smartphone) then Sens would be on a potential PE of less than 2 ! All based on rough figures of course. Discuss :-)
billy3: Sensyne Health PLC 13 November 2020 Sensyne Health appoints President, North America, to lead US expansion Oxford, U.K. 13 November 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company's North American operations, building Sensyne's presence in the US and recruiting a US-based team. Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing roles at Zynx Health and ambulatory electronic health records provider Practice Partner. Derek is a US national and will be based in the US. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "I'm delighted that Derek is joining the Sensyne team. His extensive experience, combined with a deep knowledge of US healthcare technology and US health systems, will be invaluable as we further capitalise on what we have already achieved in the UK by driving forward our expansion into the US and building a transatlantic business." Derek Baird, said: "I've been impressed with the progress that Sensyne has already made in the UK in such a short space of time. It is clear the value that Sensyne delivers in the UK is equally applicable to US heathcare systems and life sciences companies. I'm excited to bring the Sensyne vision and unique business model to the US market."
billy3: RNS Number : 6245A Sensyne Health PLC 30 September 2020 Sensyne Health announces collaboration with the University of Oxford to provide software for remote symptom data collection and analytics for a Phase II clinical trial in care homes of adalimumab to prevent respiratory failure due to COVID-19 Highlights : · Sensyne's software for remote symptom data collection and analytics will support researchers in academia and the pharmaceutical industry to undertake clinical trials during the pandemic, particularly within the community environment · Collaboration with the University of Oxford for the AVID-CC Phase II clinical trial in care homes of the anti-TNF drug adalimumab funded by the Wellcome Trust · Further agreements to use Sensyne's capabilities in other clinical trials are in advanced discussions Oxford, U.K. 30 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces a collaboration with the University of Oxford in which Sensyne will provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19. The trial is funded by the COVID-19 Therapeutics Accelerator, an initiative set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with support from an array of public and philanthropic donors. The purpose of the trial is to assess the effectiveness of Adalimumab in preventing progression to respiratory failure or death due to COVID-19 infection. A particular feature of this trial, supported by Sensyne's software, is the remote collection of data on symptoms, vital signs and activities of daily living from clinical trial subjects in care homes, followed by a phase of exploratory data analysis using Sensyne's machine learning algorithms. The software is based on Sensyne's CVm-Health ™ software application for tracking COVID-19 symptoms launched earlier this year. The use of CVm-Health will allow clinical trial participants in care homes to record their symptoms and vital signs and enable trial investigators to access such data remotely. The 'Good Neighbour' aspect of CVm-Health, whereby a carer, with consent, can enter data on behalf of an individual, is an important feature that facilitates clinical trials in the community care environment. Under the trial protocol, and with the consent of participants, anonymised data recorded by the application during the trial will be analysed using machine learning algorithms developed by Sensyne. Sensyne is in advanced discussions for the use of its remote symptom and vital sign data collection software and analytics expertise by other clinical researchers seeking to undertake drug trials during the COVID-19 pandemic, particularly trials within community settings such as care homes. Further announcements will be made as such discussions reach agreement. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Sensyne is at the forefront of developing advanced remote monitoring software and clinical AI tools that enable clinical research to be undertaken during the new circumstances caused by the COVID-19 pandemic. We are delighted to be working with the University of Oxford on this important new trial of Adalimumab , pioneering new clinical research techniques in the community environment." Professor Duncan Richards FRCP, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU), formerly Head of Clinical Pharmacology and Experimental Medicine for GSK (until 2019), who is the Chief Investigator for the AVID-CC trial , said: " We have been impressed by Sensyne Health's digital health and clinical AI capabilities. We are excited by the opportunity that that flexible electronic diaries for remote data collection and analytics, such as CVm-Health for patients and carers to contribute to information collected in clinical trials. This pandemic has highlighted the need to re-examine the ways in which we collect data. We are delighted to be working with Sensyne and are excited by the potential for unique insights that may come from exploratory analyses of the anonymised clinical trial data using their proprietary machine learning algorithms." -ENDS-
mrc2u: >>gilesyDisagree that most CEOs would have been sacked because of SENS share price performance. They raised a stack of cash at IPO to pursue a plan and are getting on with it. They claim up front to have hit all the 24 month objectives from IPO early. No reason to fire a CEO for setting out a plan, getting it funded and then delivering against it. The bonus shambles is the only reason so far to fire Drayson and he has at least tried to deploy some fig leaves on thatSENS shares down from 175p to 50p giving a market cap of around GBP60m. Worth looking at private company Benevolent AI, where Woodford also had a big stake. Its value on latest raise was halved from USD2bn to USD1bn. Latest results show revenue of GBP6m and cash consumed if GBP50m. If SENS does get revenues north of GBP2m, which looks likely, and burns about 15m it ought to be worth more than one twelfth of Benevolent after a huge crash in Benevolent's valie. It would also still have 18 months to two years cash left with any additional revenues extending the runwayYes it's hard to value this. You have merely shown that it is easy to troll itMrC
Sensyne Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Sensyne He..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210805 02:47:43